Amgen Gestione

Gestione criteri di controllo 3/4

Amgen Il CEO è Bob Bradway, nominato in May2010, e ha un mandato di 14.5 anni. la retribuzione annua totale è $ 22.64M, composta da 7.9% di stipendio e 92.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.12% delle azioni della società, per un valore di R$ 1.05B. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.8 anni e 7.9 anni.

Informazioni chiave

Bob Bradway

Amministratore delegato

US$22.6m

Compenso totale

Percentuale dello stipendio del CEO	7.9%
Mandato del CEO	14.5yrs
Proprietà del CEO	0.1%
Durata media del management	4.8yrs
Durata media del Consiglio di amministrazione	7.9yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Bob Bradway rispetto agli utili di Amgen?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$4b
Jun 30 2024	n/a	n/a	US$3b
Mar 31 2024	n/a	n/a	US$4b
Dec 31 2023	US$23m	US$2m	US$7b
Sep 30 2023	n/a	n/a	US$8b
Jun 30 2023	n/a	n/a	US$8b
Mar 31 2023	n/a	n/a	US$8b
Dec 31 2022	US$21m	US$2m	US$7b
Sep 30 2022	n/a	n/a	US$7b
Jun 30 2022	n/a	n/a	US$7b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$22m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$6b
Mar 31 2021	n/a	n/a	US$7b
Dec 31 2020	US$20m	US$2m	US$7b
Sep 30 2020	n/a	n/a	US$7b
Jun 30 2020	n/a	n/a	US$7b
Mar 31 2020	n/a	n/a	US$8b
Dec 31 2019	US$20m	US$2m	US$8b
Sep 30 2019	n/a	n/a	US$8b
Jun 30 2019	n/a	n/a	US$8b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$19m	US$2m	US$8b
Sep 30 2018	n/a	n/a	US$2b
Jun 30 2018	n/a	n/a	US$2b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$17m	US$2m	US$2b

Compensazione vs Mercato: La retribuzione totale di Bob ($USD 22.64M ) è superiore alla media delle aziende di dimensioni simili nel mercato BR ($USD 5.71M ).

Compensazione vs guadagni: La retribuzione di Bob è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Bob Bradway (61 yo)

14.5yrs

Mandato

US$22,643,650

Compensazione

Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Bradway	Chairman	14.5yrs	US$22.64m	0.12% R$ 1.1b
Peter Griffith	Executive VP & CFO	4.8yrs	US$7.57m	0.0046% R$ 41.5m
Esteban Santos	Executive Vice President of Operations	8.3yrs	US$7.21m	0.011% R$ 102.7m
David Reese	Executive VP & CTO	less than a year	US$7.90m	0.0094% R$ 84.5m
Murdo Gordon	Executive Vice President of Global Commercial Operations	6.2yrs	US$8.24m	0.0075% R$ 67.1m
Matthew Busch	Chief Accounting Officer & VP of Finance	1.3yrs	Nessun dato	0.00062% R$ 5.6m
James Bradner	Executive VP of Research & Development and Chief Scientific Officer	less than a year	Nessun dato	Nessun dato
Justin Claeys	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Jonathan Graham	Executive VP	9.3yrs	US$7.24m	0.0046% R$ 41.8m
Nancy Grygiel	Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer	4.8yrs	Nessun dato	0.0013% R$ 11.8m
Kave Niksefat	Senior Vice President of Global Marketing & Access	less than a year	Nessun dato	Nessun dato
Derek Miller	Senior Vice President of Human Resources	2.8yrs	Nessun dato	0.0012% R$ 10.4m

4.8yrs

Durata media

56.5yo

Età media

Gestione esperta: Il team dirigenziale di AMGN34 è considerato esperto (durata media dell'incarico 4.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Bradway	Chairman	13.1yrs	US$22.64m	0.12% R$ 1.1b
Robert Eckert	Lead Independent Director	11.9yrs	US$419.92k	0.0013% R$ 11.8m
David Baltimore	Co-Chair of Scientific Advisory Board	no data	US$292.01k	Nessun dato
Charles Sigal	Co-Chair of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Amy Miles	Independent Director	4.3yrs	US$359.92k	0.000080% R$ 719.6k
Charles Holley	Independent Director	7.8yrs	US$369.92k	0.00023% R$ 2.1m
Greg Garland	Independent Director	11.1yrs	US$379.92k	0.0023% R$ 20.7m
Ellen Kullman	Independent Director	8.1yrs	US$360.29k	0.000080% R$ 719.6k
Brian Druker	Independent Director	6.5yrs	US$359.92k	0.00015% R$ 1.3m
Tyler Jacks	Independent Director	12.5yrs	US$339.92k	0.00051% R$ 4.6m
Wanda Austin	Independent Director	6.9yrs	US$359.92k	0.0012% R$ 11.0m
S. Ishrak	Independent Director	3.3yrs	US$366.47k	0.00017% R$ 1.5m

7.9yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AMGN34 sono considerati esperti (durata media dell'incarico 7.9 anni).

Amgen Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Howard Chang Joins Amgen as Senior Vice President of Research and Chief Scientific Officer, Effective December 16, 2024

Amgen Inc. Appoints Anumita Tripathi as Director of Corporate Affairs for Amgen India

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Inc. Announces Executive Changes

Amgen Inc. Announces Management Changes

Recent updates

Howard Chang Joins Amgen as Senior Vice President of Research and Chief Scientific Officer, Effective December 16, 2024

Amgen and AstraZeneca Announce Positive Top-Line Results from the Phase 3 WayPOINT Trial in Patients with Chronic Rhinosinusitis with Nasal Polyps

Amgen Inc. Provides Earnings Guidance for the Full Year 2024

Amgen Inc. Announces Dividend for the Fourth Quarter of 2024, Payable on December 9, 2024

Amgen Inc. to Report Q3, 2024 Results on Oct 30, 2024

Amgen Announces Presents Positive Top-Line Results from the Phase 3 MINT Trial Evaluating the Efficacy and Safety of UPLIZNA

Amgen Inc. Appoints Anumita Tripathi as Director of Corporate Affairs for Amgen India

Amgen Announces Otezla®? (Apremilast) Now Available in the U.S. for Moderate to Severe Plaque Psoriasis

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q2, 2024 Results on Aug 06, 2024

Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto

Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)

FDA Approves Amgen's IMDELLTRA™? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q1, 2024 Results on May 02, 2024

Amgen to Submits Marketing Authorization Application to the European Medicines Agency

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen Presents New Research on Otezla (Apremilast) at AAD 2024

Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q4, 2023 Results on Feb 06, 2024

Amgen Provides Regulatory Update on Status of LUMAKRAS (Sotorasib)

Amgen Inc. Announces Executive Changes

Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023

Amgen Inc. Presents New Data That Show Blood Pressure Decides for Results Treated with Krystexxa (PegLOTICase)

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Amgen Inc. to Report Q3, 2023 Results on Oct 31, 2023

Amgen Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 8, 2023

Amgen Presents New LUMAKRAS (Sotorasib) Plus Vectibix (Panitumumab) Data in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Amgen Inc. to Present New Research from Oncolfolio and Pipeline At ESMO2023

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Presents New Lumakras® (Sotorasib) Plus Chemotherapy Data in First-Line Kras G12c Nsclc At Wclc

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen Presents Phase 2 OLPASIRan Data at ESC 2023

Amgen Announces to Discuss Application for LUMAKRAS (Sotorasib) for Treatment of KRAS G12C-Positive NSCLC at FDA Advisory Committee Meeting

Amgen Inc. Announces Management Changes

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Amgen Inc. to Report Q2, 2023 Results on Aug 03, 2023

Amgen Inc. Announces U.S. Food and Drug Administration Approves Supplemental Biologics License Application for BLINCYTO

Amgen Presents New Lumakras® (Sotorasib) Codebreak 200 CNS Data At Asco 2023

Amgen Presents New Scientific and Clinical Research Across its Diverse Oncology Portfolio and Pipeline at ASCO 2023

Amgen Presents New Research on Otezla® (Apremilast) in Psoriatic Arthritis At Eular 2023

Amgen Inc. Announces New Data from A Real-World Study of Nearly Half of Million Postmenopausal Women with Osteoporosis in the U.S. Medicare Program

AstraZeneca and Amgen Announce Approval of TEZSPIRE® (tezepelumab-ekko) in the US

Amgen Inc. to Report Q4, 2022 Results on Jan 31, 2023

Amgen Announces ECOG-ACRIN Cancer Research Group Results

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media